On November 19, 2009, Crew, Andrew P.; Jin, Meizhong; Kadalbajoo, Mridula; Kleinberg, Andrew; Mulvihill, Mark J.; Wang, Jing published a patent.Name: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone The title of the patent was Substituted imidazopyrazines and imidazotriazines as ACK1 inhibitors and their preparation. And the patent contained the following:
The invention relates to fused pyridine-based bicyclic compounds having the structure of formula I, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. Compounds of formula I wherein A is CH and N; Q1 is X1Y1Z1, 1-phenylbenzimidazol-5-yl and carbazolyl; X1 is (un)substituted 5- to 10-membered cyclic ring; Y is CO, O, S, SO, SO2, etc.; Z1 is (un)substituted 5- to 10-membered cyclic ring and C1-6 alkoxy; R1 is SH and derivatives, (un)substituted C1-6 alkyl, (un)substituted 5,6-bicyclic aryl and (un)substituted 3- to 6-membered ring; and pharmaceutically acceptable salt thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their ACK1 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 0.1759 μM. The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Name: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone
The Article related to imidazopyrazine imidazotriazine preparation ack1 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Name: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone